Comparing two treatment approaches for moderate to severe inflammatory bowel disease

This study is testing a medication called infliximab, given as a subcutaneous injection (under the skin), for people with moderate to severe Crohn's disease. Researchers want to see whether the medication works better when you take it by itself, or when you combine it with other immunosuppressive medications. The trial will measure success by checking whether patients achieve remission (symptom relief) and healing of the bowel lining.

Crohn's disease is a serious condition that causes inflammation in the digestive tract, and some patients don't respond well to currently available treatments or cannot tolerate them. This trial is exploring whether combining this medication with other drugs might be more effective than using it alone, and whether the subcutaneous (under-the-skin) form of delivery works well for newly diagnosed or treatment-resistant patients.